Log In Get Started
Insider Trading April 10, 2026 04:04 PM

Precipio COO Purchases 19 Shares, Adding $530 to Personal Stake

Small insider buy comes as company reports positive cash flow and revenue growth in Q4 2025

By Maya Rios PRPO
Precipio COO Purchases 19 Shares, Adding $530 to Personal Stake
PRPO

Precipio, Inc. (NASDAQ: PRPO) Chief Operating Officer Sabet Ahmed Zaki acquired 19 shares of the company’s common stock on April 1, 2026, at $27.93 per share, a transaction valued at $530. The trade, executed under a 10b5-1 plan and reported on a Form 4 filing with the SEC, leaves Zaki with direct ownership of 1,034 shares. The purchase coincides with a stock that has risen 415% over the past year and 9.5% in the last week, and follows the company's Q4 2025 results showing a move to positive cash flow and $6.7 million in quarterly revenue driven largely by Pathology Services.

Key Points

  • COO Sabet Ahmed Zaki purchased 19 shares of Precipio at $27.93 per share on April 1, 2026, totaling $530, and now directly owns 1,034 shares.
  • The trade was executed under a 10b5-1 plan and reported on a Form 4 with the SEC; the stock has risen 415% over the past year and 9.5% in the last week.
  • Precipio reported Q4 2025 revenue of $6.7 million and a shift to positive cash flow, largely driven by its Pathology Services division; InvestingPro analysis cited the company as appearing undervalued with a "GREAT" Financial Health score.

Precipio, Inc. (NASDAQ: PRPO) Chief Operating Officer Sabet Ahmed Zaki reported a purchase of 19 shares of the company's common stock on April 1, 2026. According to the Form 4 filed with the Securities and Exchange Commission, the shares were acquired at $27.93 each, for a total transaction value of $530.

The filing states the trade was executed pursuant to a 10b5-1 trading plan adopted by the reporting person. Following the transaction, Zaki directly holds 1,034 shares of Precipio common stock.

The insider purchase arrives while the stock is trading at $27.25 and after a period of strong market performance. Over the past 12 months, the share price has appreciated 415%, and the stock has gained 9.5% in the most recent week.

Market analysis cited in the filing notes that InvestingPro evaluates Precipio as appearing undervalued at current levels and assigns the company a "GREAT" Financial Health score. The filing also references a comprehensive Pro Research Report on PRPO available through InvestingPro.

Separately, Precipio reported fourth-quarter 2025 financial results that the company characterized as a milestone: a shift to positive cash flow generation for the period. Revenue for Q4 2025 totaled $6.7 million, with the company attributing much of that revenue to its Pathology Services division. The earnings release highlights what the company describes as progress in its financial position.

Despite the favorable results on cash flow and revenue, the stock experienced a decline after the earnings announcement, though the filing notes that precise intraday or subsequent price movements are not the focus of the report. The company’s recent filings did not include any mention of analyst upgrades or downgrades.

This transaction and the accompanying disclosures provide investors with updated information on insider ownership, recent operating results, and third-party assessments of Precipio’s financial condition. The 10b5-1 designation of the purchase is disclosed on the Form 4, and the company’s latest quarterly results remain a central datapoint in evaluating recent momentum.

Risks

  • The insider purchase was made under a 10b5-1 plan, indicating the trade may have been prearranged rather than timed to new information - this affects interpretation of insider intent.
  • The stock experienced a decline following the Q4 2025 earnings release, demonstrating short-term volatility in market reaction to reported results.
  • Company revenue for the quarter was driven largely by the Pathology Services division, indicating concentrated operational dependence on that segment for recent performance.

More from Insider Trading

Immunovant CLO Sells $128K in Stock to Cover RSU Taxes as Company Faces Mixed Analyst Reaction After Trial Miss Apr 10, 2026 Roku Media President Sells $21.6M in Class A Shares, Exercises Equivalent Options Apr 10, 2026 U.S. Gold Director Adds to Position, Buying $146,300 in Shares Apr 10, 2026 Williams-Sonoma CFO Disposes of $267,410 in Stock via 10b5-1 Plan Apr 10, 2026 Williams-Sonoma EVP Karalyn Yearout Sells $436K in Stock Under 10b5-1 Plan Apr 10, 2026